When I was finishing up pharmacy school (2013), the landscape of Hep-C therapy was drastically changing. Two new drugs, boceprevir and telaprevir, were fresh on the market and were "game changers" according to any and everyone. In fact--I presented these new protease inhibitors (in all their majesty) during my residency interviews.
Now it's 2016 and they're both gone.
Read More